ライフサイエンスコーパス: vein thrombosis

1 enous thrombosis (122 VTE and 29 superficial vein thrombosis).

2 cancer admitted to SPCUs had a femoral deep vein thrombosis.

3 edema (p=0.009) independently predicted deep vein thrombosis.

4 DT in ATTRACT patients with iliofemoral deep vein thrombosis.

5 % mortality, 43.7% disability, and 9.8% deep vein thrombosis.

6 unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

7 eminated tuberculosis complicated by splenic vein thrombosis.

8 Three (2.9%) grafts were lost due to portal vein thrombosis.

9 led to a complete resolution of the splenic vein thrombosis.

10 ism manifested as pulmonary embolism or deep vein thrombosis.

11 age, sex, treatment, tumor size, and portal vein thrombosis.

12 or placebo stockings) in patients with deep vein thrombosis.

13 ay less than 2 days, or had preexisting deep vein thrombosis.

14 ent had central venous catheter-related deep vein thrombosis.

15 patients (84.6%) had cannula-associated deep vein thrombosis.

16 st thrombotic syndrome in patients with deep vein thrombosis.

17 alysed were mortality and recurrence of deep vein thrombosis.

18 present in 62.5% of the patients with portal vein thrombosis.

19 d bloodstream infection and symptomatic deep-vein thrombosis.

20 hrodysesthesia, cerebral ischaemia, and deep-vein thrombosis.

21 was no incidence of hepatic artery or portal vein thrombosis.

22 between extrapulmonary tuberculosis and deep vein thrombosis.

23 e liver cell necrosis, together with central vein thrombosis.

24 of infection and presenting with left portal vein thrombosis.

25 er change of complications related to portal vein thrombosis.

26 us sinus thrombosis, along with left jugular vein thrombosis.

27 ll of them developed cannula-associated deep vein thrombosis.

28 elationship between folate status and portal vein thrombosis.

29 omboplastin time, prothrombin time, and deep vein thrombosis.

30 or VTEs, such as pulmonary embolism and deep vein thrombosis.

31 femoral and jugular cannula-associated deep vein thrombosis.

32 ted risk factors for cannula-associated deep vein thrombosis.

33 ans, 92 (34%, 95% CI 28-40) had femoral deep vein thrombosis.

34 e (PTS) in patients with acute proximal deep vein thrombosis.

35 mbolic events, driven by a reduction in deep vein thrombosis.

36 and survival (p=0.45) were unrelated to deep vein thrombosis.

37 to abdominal complications, all after renal vein thrombosis.

38 possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterioratio

39 ainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obesity (9

40 tent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylaxis to

41 thromboembolic events (6/11), that is, deep vein thrombosis (4), transitory ischemic attacks (2), pu

42 lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and stroke

43 offer patients with symptomatic superficial-vein thrombosis a less burdensome and less expensive ora

44 or interventions for pulmonary embolism/deep vein thrombosis (A 0%, B 24%, C 76%), inferior vena cava

45 lly, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrome, pn

46 tus of FHMI were highest for unprovoked deep vein thrombosis (adjusted hazard ratio, 1.69; 95% confid

47 my was associated with development of portal vein thrombosis after surgery (P = 0.01).

48 Cannula-associated deep vein thrombosis after venovenous extracorporeal membrane

49 ondary endpoints were the occurrence of deep vein thrombosis alone, pulmonary embolism alone.

50 aluations revealed a mild ascites and portal vein thrombosis although the patient received proper ant

51 ficacy outcomes in patients with superficial-vein thrombosis and additional risk factors given either

52 ss this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in peptidyla

53 embolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as pharm

54 ulmonary embolism associated with lower-limb vein thrombosis and at least 1 criterion for severity we

55 bute to pathologies, including arterial/deep vein thrombosis and atherosclerosis.

56 techniques (compression ultrasound for deep-vein thrombosis and computed tomography pulmonary angiog

57 nary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism were

58 Effects of stasis-induced deep vein thrombosis and fibrinolysis on thrombosis were exam

59 of posttransplant cure, extensive mesenteric vein thrombosis and intestinal infarction, total intesti

60 and inflammatory activity of T cells in deep vein thrombosis and its consequences for venous thrombus

61 ifen and 16 with placebo, including one deep vein thrombosis and one stage I endometrial cancer with

62 ncreatitis and is associated with splanchnic vein thrombosis and pancreatic head necrosis.

63 rs for stricture development were splanchnic vein thrombosis and pancreatic head parenchymal necrosis

64 infusion is recommended for symptomatic deep vein thrombosis and portal and mesenteric vein thrombosi

65 source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

66 Deep Vein Thrombosis and pulmonary embolism (DVT/PE) is one o

67 In many patients with deep vein thrombosis and pulmonary embolism (venous thromboem

68 e initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as for lo

69 prise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous t

70 e treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been shown in

71 eon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has been

72 Because the clinical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecific, i

73 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assessed.

74 venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the evidenc

75 Deep vein thrombosis and pulmonary embolism, collectively def

76 and Measures: Rates of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed by dup

77 s thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common comp

78 ient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism.

79 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

80 gents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism.

81 es it the drug of choice for preventing deep vein thrombosis and pulmonary embolism.

82 d and unprovoked events, as well as for deep vein thrombosis and pulmonary embolism.

83 ancer patients are at increased risk of deep vein thrombosis and pulmonary embolism.

84 as a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism.

85 nd included serious adverse events (eg, deep vein thrombosis and systemic complications) and minor ad

86 osis of proximal or inferior vena caval deep vein thrombosis and treated with CDT from 2005 to 2010.

87 ween FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by modifiable athe

88 f rare subgroups of pediatric VTE (eg, renal vein thrombosis), and will be important to ultimately gu

89 A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism.

90 spitalized for proximal lower-extremity deep vein thrombosis, and 3649 patients (4.1%) underwent CDT.

91 embolism, 25 (22%) had a superior mesenteric vein thrombosis, and 4 (3%) had superior mesenteric arte

92 h an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive anticoagul

93 or adverse cardiovascular events, splanchnic vein thrombosis, and bleeding in a cohort with cirrhosis

94 torenal syndrome, hepatichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.

95 abetes mellitus, renal insufficiency, portal vein thrombosis, and poor performance status.

96 uch as ventilator-associated pneumonia, deep vein thrombosis, and pressure sores; and shortened the d

97 or venous thromboembolism, proximal leg deep vein thrombosis, and pulmonary embolism developing durin

98 ncluding myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism.

99 btained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism.

100 e cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

101 patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump throm

102 y infection, hemorrhage, renal failure, deep vein thrombosis, and uncontrollable intracranial hyperte

103 C filter vs IVC filter on PE, fatal PE, deep vein thrombosis, and/or mortality in trauma patients.

104 sm, progression or recurrence of superficial vein-thrombosis, and all-cause mortality at 45 days in t

105 sm, progression or recurrence of superficial vein-thrombosis, and all-cause mortality, and was not as

106 tions included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a statin.

107 s and management of acute symptomatic portal vein thrombosis are essential.

108 Outcomes for graft and deep vein thrombosis are not favorable.

109 Left sided abscess and portal vein thrombosis are rare and hence reported.

110 artery on the same side as the isolated calf vein thrombosis as well as on the opposite side.

111 ncident (i.e., new) proximal lower-limb deep-vein thrombosis, as detected on twice-weekly lower-limb

112 Portal vein thrombosis at listing was not associated with lower

113 Portal vein thrombosis at LT is associated with early (90 days)

114 , we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban (at

115 eatment period or asymptomatic proximal deep-vein thrombosis at the end of treatment.

116 lecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehydration.

117 ference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus

118 ymptoms plus imaging-confirmed proximal deep vein thrombosis but no chest imaging.

119 ep vein thrombosis and portal and mesenteric vein thrombosis, but there are unresolved issues regardi

120 and are believed to reduce the risk of deep vein thrombosis by 40%.

121 Stasis of venous blood triggers deep vein thrombosis by activating coagulation, yet its effec

122 Superficial-vein thrombosis can lead to deep-vein thrombosis and pul

123 ion in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0.77, 95

124 ic disc and macula in patients with cerebral vein thrombosis (CVT) without papilledema.

125 reatment of incidental portal and mesenteric vein thrombosis depends on estimated impact on transplan

126 ality, ventilator-associated pneumonia, deep vein thrombosis, depression, and hostility.

127 ntly develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant the

128 n-interventional study of patients with deep-vein thrombosis, done in hospitals and community care ce

129 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonary emb

130 enous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a

131 s thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is th

132 ely may be at higher risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

133 Deep vein thrombosis (DVT) and pulmonary embolism are collect

134 oring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule were

135 curate detection of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical problem.

136 Deep vein thrombosis (DVT) is a common but unpredictable comp

137 Deep vein thrombosis (DVT) is a common cardiovascular disease

138 ment of suspected ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge beca

139 The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persistent

140 Deep-vein thrombosis (DVT) is regarded a chronic disease as i

141 Deep vein thrombosis (DVT) isolated to the calf veins (distal

142 ulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.

143 hs) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life

144 on on the use of compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthopedic

145 Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates remain

146 Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to 112 per 100 000 p

147 Deep vein thrombosis (DVT) with its major complication, pulmo

148 Deep vein thrombosis (DVT), caused by alterations in venous h

149 , or a first unprovoked isolated distal deep vein thrombosis (DVT), generally should be treated for 3

150 first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and

151 In patients with acute deep vein thrombosis (DVT), pharmacomechanical catheter-direc

152 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and VTE

153 l clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive patien

154 of them have proximal limb-threatening deep vein thrombosis (DVT).

155 th formation and resolution of clots in deep vein thrombosis (DVT).

156 as a complimentary approach to isolated calf vein thrombosis (DVT).

157 ty, all-cause mortality, and subsequent deep vein thrombosis (DVT).

158 ution in humans after acute symptomatic deep vein thrombosis (DVT).

159 asia/VLG) after initiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was not kno

160 oup, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemotherapy

161 e liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome after Mes

162 Eligible patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolism (EI

163 ics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis enrolled 1650 patients aged 65 years or

164 were qualitative differences such that deep vein thrombosis exclusively afflicted the immunosuppress

165 The prevalence of deep vein thrombosis following decannulation from extracorpor

166 e to: 1) analyze the cannula-associated deep vein thrombosis frequency after venovenous extracorporea

167 years or older with symptomatic superficial-vein thrombosis from 27 sites (academic, community hospi

168 g week lowered the risk of proximal leg deep vein thrombosis (hazard ratio, 0.46; 95% CI, 0.27-0.77;

169 risk for developing cannula-associated deep vein thrombosis (hazard ratio, 0.98; 95% CI, 0.98-1.00;

170 a predictor for developing proximal leg deep vein thrombosis (hazard ratio, 1.25; 95% CI, 1.06-1.46;

171 the YEARS algorithm (clinical signs of deep-vein thrombosis, hemoptysis, and pulmonary embolism as t

172 s of treated HIV-infected patients with deep vein thrombosis, hepatitis C, renal impairment, thyroid

173 0.003]; mainly driven by a reduction in deep vein thrombosis (HR 0.523; 95% CI 0.349-0.783, P = 0.002

174 I], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.01) an

175 pliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed in sub

176 rasonography for women with symptoms of deep-vein thrombosis; if the results were positive (i.e., a c

177 n thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from venous t

178 osite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism, sym

179 r limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thr

180 eculated that the underlying cause of portal vein thrombosis in our case was coronaviruses.

181 ne prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palli

182 Management of portal vein thrombosis in patients with cirrhosis is more contr

183 to fondaparinux for treatment of superficial-vein thrombosis in terms of symptomatic deep-vein thromb

184 ymptomatic, radiographically confirmed, deep-vein thrombosis in the arm or leg or pulmonary embolism.

185 The prevalence of deep vein thrombosis in the cannulated vessel following extra

186 ibe the prevalence of postdecannulation deep vein thrombosis in the cannulated vessel in adults who h

187 ies are more effective in prevention of deep vein thrombosis in the elective total knee replacement p

188 -sided PICC were more likely to develop deep-vein thrombosis in the ipsilateral arm (HR 3.37, 95% CI

189 significantly more likely to develop a deep-vein thrombosis in the ipsilateral arm compared with the

190 2; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% confide

191 ics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or older

192 However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients with

193 In contrast, in a model of vein thrombosis induced by flow restriction in the infer

194 e the thrombus and vein wall rapidly on deep vein thrombosis induction and remain in the tissue throu

195 ndomized trial, 391 patients with acute deep vein thrombosis involving the iliac or common femoral ve

196 Deep vein thrombosis is a major global health issue, responsi

197 tment of acute proximal lower-extremity deep vein thrombosis is increasing in the United States and h

198 tients with cirrhosis, development of portal vein thrombosis is often insidious and remains undetecte

199 , acute RV dysfunction, with or without deep vein thrombosis, is more common, but acute LV systolic d

200 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the addition

201 Pediatric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic synd

202 eading cause of maternal mortality, and deep vein thrombosis leads to maternal morbidity, with postth

203 onary embolism at 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 months

204 tors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paralysis,

205 artery disease, obesity, hypertension, deep vein thrombosis, male sex, high-sensitivity C-reactive p

206 tion induced femoral cannula-associated deep vein thrombosis more frequently than femorojugular cannu

207 also contribute to the pathogenesis of deep vein thrombosis, myocardial infarction and stroke.

208 lity in the developed world, underlying deep vein thrombosis, myocardial infarction, and stroke.

209 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and dehy

210 erse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2), he

211 entions; n=15 028) were included in the deep vein thrombosis network, 12 in the pulmonary embolism ne

212 cacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or all-cau

213 atheter-related blood stream infection, deep vein thrombosis, occlusion, pain, infiltration, bleeding

214 Segmental left portal vein thrombosis occurred in 1 patient and intraluminal l

215 Deep vein thrombosis occurred in 5 patients.

216 Early graft loss from renal vein thrombosis occurred in two singly implanted kidneys

217 m (pulmonary embolism or any lower-limb deep-vein thrombosis) occurred in 103 of 991 patients (10.4%)

218 Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism.

219 our participants with a scan showing no deep vein thrombosis on admission developed a deep vein throm

220 ein thrombosis on admission developed a deep vein thrombosis on repeat scanning over 21 days.

221 t least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embolism

222 ed for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their most

223 rise from intravenous obstruction after deep vein thrombosis or from extrinsic venous compression.

224 romboembolism defined as a composite of deep vein thrombosis or non-fatal or fatal pulmonary embolism

225 dependent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC

226 ant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9.3% (

227 ymptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive oral ap

228 tcome was VTE (defined as patients with deep vein thrombosis or pulmonary embolism) that occurred dur

229 n, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assessed.

230 newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new user

231 rebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respiratory

232 after surgery or confirmed symptomatic deep vein thrombosis or pulmonary embolism).

233 outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression or re

234 vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression or re

235 10% [67/690]; p=0.92) or recurrence of deep vein thrombosis (OR 0.93 [95% CI 0.66-1.31]; 6.4% [70/10

236 statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults were in

237 llected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

238 P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

239 In patients with acute iliofemoral deep vein thrombosis, PCDT did not influence the occurrence o

240 compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41,

241 improve compliance with antibiotic and deep vein thrombosis prophylaxis, and improve overall percept

242 gement, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic intensifi

243 l complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

244 micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke.

245 c venous thromboembolism was defined as deep vein thrombosis, pulmonary embolism, or both, diagnosed

246 osite of symptomatic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thromboem

247 ranging from repeated thrombophlebitis, deep vein thrombosis, pulmonary embolism, transitory ischemic

248 ), whereas most venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%) or ve

249 Portal vein thrombosis (PVT) and different cardiovascular disor

250 ts of liver cirrhosis associated with portal vein thrombosis (PVT) can be effectively treated by tran

251 In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence

252 Portal vein thrombosis (PVT) is common in patients with cirrhos

253 Portal vein thrombosis (PVT) occurs frequently in hepatocellula

254 survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y-loaded

255 e hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioembolizati

256 The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients receiv

257 with chronic noncirrhotic, nontumoral portal vein thrombosis (PVT), the usually recommended strategy

258 from portal hypertension but also by portal vein thrombosis (PVT).

259 enic reporter mice, we demonstrate that deep vein thrombosis-recruited TEM receive an immediate antig

260 nificant difference in the incidence of deep vein thrombosis (relative risk, 1.76 [95% CI, 0.50-6.19]

261 st thrombotic syndrome in patients with deep vein thrombosis remains unknown.

262 illation, supraventricular tachycardia, deep vein thrombosis, respiratory depression, atelectasis, pn

263 .97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25];

264 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25];

265 8 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08];

266 aroxaban ranked first for prevention of deep vein thrombosis (RR 0.12 [95% CrI 0.06-0.22]).

267 We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of

268 Deep vein thrombosis screening was performed using a rigorous

269 dd-Chiari Syndrome) and in those with portal vein thrombosis (second section); and we briefly comment

270 served in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary strict

271 eagues report on the relevance of splanchnic vein thrombosis (SVT) as a marker of occult malignant di

272 tly, it has become apparent that superficial vein thrombosis (SVT) can have serious complications.

273 Antithrombotic treatment of splanchnic vein thrombosis (SVT) is a clinical challenge.

274 ombosis following a diagnosis of superficial vein thrombosis (SVT).

275 Outcomes of interest were deep vein thrombosis (symptomatic and asymptomatic), pulmonar

276 is would result in a lower incidence of deep-vein thrombosis than pharmacologic thromboprophylaxis al

277 lower incidence of proximal lower-limb deep-vein thrombosis than pharmacologic thromboprophylaxis al

278 urysmal subarachnoid hemorrhage and cerebral vein thrombosis, that are predominant in women.

279 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical cath

280 signed 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone

281 rial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-dose catheter throm

282 (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated pulmo

283 terization of pediatric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic syndro

284 Portal vein thrombosis unrelated to solid malignancy is common

285 e thrombotic vein, we identify a set of deep vein thrombosis upregulated cytokines and chemokines tha

286 During follow-up, popliteal deep-vein thrombosis was diagnosed in 1 patient (0.21%; 95% c

287 Femoral deep vein thrombosis was diagnosed in 5 of 12 patients with R

288 Cannula-associated deep vein thrombosis was found in 75 patients (71.4%) despite

289 the weighted frequency of PICC-related deep vein thrombosis was highest in patients who were critica

290 a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9%), a

291 A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (53.8%)

292 Portal vein thrombosis was independently associated with increa

293 sm (I26) or any code for deep or superficial vein thrombosis was listed as the primary cause of death

294 Deep vein thrombosis was not associated with thromboprophylax

295 Deep vein thrombosis was present only in five of 41 (12.2%) p

296 prised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure grou

297 ata regarding the secondary causes of portal vein thrombosis were normal.

298 ears, 52% women) with acute iliofemoral deep vein thrombosis were randomized to receive ultrasound-as

299 tic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban 60 mg

300 the study was the prevalence of femoral deep vein thrombosis within 48 h of SPCU admission, analysed